Clinical Trial

A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to characterize the real-world treatment patterns of omalizumab among adult patients with chronic urticaria in China using data from a regional electronic healthcare (rEHR) database. This included assessing the frequency and proportion of prescriptions across different dosages of omalizumab in real-world clinical practice.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Completed 2026-04-16
notable Enrollment increased: 2500 -> 3485 participants 2026-04-16
Trial Details
NCT Number NCT07450170
Lead Sponsor Novartis Pharmaceuticals
Conditions Chronic Urticaria
Enrollment 3,485 participants
Start Date 2026-03-10
Primary Completion 2026-03-23 (estimated)
Study Completion 2026-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-15